세계 혈관 스텐트 시장 규모는 2023년 133억 1,000만 달러, 2030년까지 210억 1,000만 달러에 달할 것으로 예상되며, 2024-2030년의 예측 기간 동안 연평균 7.90%의 성장률을 보일 전망입니다. 혈관 스텐트에 대한 수요 증가는 주로 죽상 동맥 경화증, 경동맥 질환 및 말초 동맥 질환과 같은 혈관 질환의 유병률 증가에 기인합니다. 또한, 환자 인구의 최소 침습 수술에 대한 선호도 증가, 제품 부문의 기술 발전, 다양한 혈관 스텐트의 승인 등은 향후 몇 년동안 세계 혈관 스텐트 시장을 촉진하는 요인 중 하나입니다.
혈관 스텐트 시장 역학
혈관 스텐트 시장은 현재 전 세계 사람들 사이에서 다양한 혈관 질환의 부담이 증가함에 따라 추진력을 얻고 있습니다. 혈관 장애 또는 혈관 질환은 혈관에 영향을 미치는 모든 상태를 포함합니다. 말초동맥질환(PAD), 경동맥질환, 관상동맥질환, 뇌졸중 등은 전 세계 사람들 사이에서 더 많이 발생하는 혈관 질환입니다. 예를 들어, 2019년 세계뇌졸중기구(World Stroke Organization, WSO)가 밝힌 정보에 따르면, 전 세계적으로 8,000만 명 이상의 사람들이 뇌졸중을 경험했습니다.
또한, 호주 정부의 2022년 자료에 따르면 2018년 호주에서 약 3만 8,600건의 뇌졸중이 보고되었으며, 2017-2018년 호주 성인의 약 6.2%가 심장, 뇌졸중 또는 혈관 질환과 관련된 질환을 하나 이상 앓고 있었습니다. 전 세계 다른 국가에서도 비슷한 추세를 보일 가능성이 높습니다. 이처럼 전 세계적으로 다양한 혈관 질환의 부담이 증가함에 따라 혈관 스텐트에 대한 수요가 증가하여 예측 기간 동안 세계 혈관 스텐트 시장의 성장을 가속할 것으로 예상됩니다.
또한, 저침습 수술에 대한 환자들의 선호도가 높아지면서 혈관 스텐트에 대한 수요도 증가할 것으로 예상됩니다. 풍선 혈관 성형술과 혈관 스텐트 삽입술은 바이패스 수술에 비해 침습성이 훨씬 낮고, 상대적으로 저위험, 저비용의 시술이기 때문입니다.
또한, 기업들이 혈관 스텐트 제품에 대한 보험 환급을 받음으로써 환자 집단에서 혈관 스텐트의 보급을 촉진하고 향후 몇 년동안 혈관 스텐트 시장이 확대될 가능성이 있습니다. 예를 들어, 2020년 6월 인도 관상동맥 심장 스텐트 시장의 선두주자인 SMT(Sahajanand Medical Technologies Pvt Ltd)는 프랑스 보건부(Ministry of Health and Public Affairs)로부터 Supraflex와 Supraflex Cruz에 대한 전액 상환을 확인 받았습니다.
이러한 모든 요인들이 서로 얽혀 향후 몇 년동안 혈관 스텐트 시장을 견인할 가능성이 높습니다.
그러나 혈관 스텐트와 관련된 위험과 제품의 엄격한 규제 승인 절차가 시장 성장을 억제할 가능성이 높습니다.
또한, 전례 없는 코로나19 팬데믹으로 인해 세계 혈관 스텐트 시장의 성장세는 초기에 둔화되었습니다. 전국적인 봉쇄, 감염 확산을 막기 위한 선택적 수술 중단 및 거부, 국경 간 물류 제한으로 인한 공급망 혼란 등이 혈관 스텐트 시장의 성장 둔화로 이어진 이유 중 일부입니다. 그러나 2020년 후반에 전 세계적으로 수많은 코로나19 백신이 승인되고 투여된 덕분에 의료 서비스를 포함한 다양한 영역에서 활동 재개가 크게 개선되어 혈관 스텐트 시장이 건강한 회복기에 접어들 수 있는 길이 열렸습니다.
혈관 스텐트 시장 부문별 분석
혈관 스텐트 유형 부문에서는 약물 용출형 스텐트가 향후 몇 년동안 큰 시장 점유율을 차지할 것으로 예상됩니다. 약물 용출 스텐트와 관련된 주요 장점은 안정된 관상동맥 질환에서 경피적 관상동맥 중재술(PCI) 후 스텐트 내 재협착률을 베어메탈 스텐트(BMS)에 비해 효율적으로 감소시킨다는 점입니다. 여러 연구에서 약물 용출 스텐트(DES)는 고유 관상동맥 병변에서 BMS에 비해 재협착률을 70% 이상 감소시키는 것으로 입증되었습니다. 따라서 현재 PCI 수술 시 DES를 삽입하는 것이 외과 의사들이 선호하는 것으로 여겨지고 있으며, 이에 따라 DES 혈관 스텐트에 대한 수요가 증가하고 있습니다.
이 보고서는 세계 혈관 스텐트 시장에 대해 조사 분석했으며, 시장 규모와 예측, 촉진요인 및 과제, 기업 및 제품 프로파일 등의 정보를 전해드립니다.
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2030 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population
The global vascular stents market was valued at USD 13.31 billion in 2023, growing at a CAGR of 7.90% during the forecast period from 2024 to 2030, to reach USD 21.01 billion by 2030. The increase in demand for vascular stents is predominantly attributed to the growing prevalence of vascular disorders such as atherosclerosis, carotid artery diseases, and peripheral artery diseases, among others. In addition, growing preferences for minimally invasive surgeries among the patient population, growing technological advancement in the product arena, and approval of various vascular stents, among others are some of the factors responsible for driving the global vascular stents market in the forthcoming years.
Vascular Stents Market Dynamics:
The market for vascular stents is gathering momentum at present owing to the rising burden of various vascular disorders among the population across the globe. Vascular disorders or diseases include any condition that affects the blood vessels. Peripheral artery diseases (PAD), carotid artery diseases, coronary artery diseases, stroke are some of the types of vascular disorders which are more prevalent among the worldwide population. For instance, according to the facts revealed by the World Stroke Organization (WSO) in the year 2019, globally, over 80 million people were living who have experienced a stroke.
In addition, as per the Australian Government 2022 data, approximately 38,600 strokes were reported in the country in the year 2018 and about 6.2% of Australian adults (1.2 million) had one or more conditions related to heart, stroke, or vascular diseases in 2017-18. Similar trends are likely to observe in other countries across the globe. Thus, the rising burden of various vascular diseases worldwide is expected to increase the demand for vascular stents thereby augmenting the global vascular stents market growth during the forecast period.
Moreover, rising preferences for minimally invasive surgeries among patients are also anticipated to raise the demand for vascular stents. This is because as compared to bypass surgery, balloon angioplasty and vascular stent placement are much less invasive and relatively low-risk, low-cost procedures.
Additionally, companies receiving reimbursement for their vascular stents products could also increase the market of these devices in the upcoming years as it will raise the adoption of these devices among the patient pool. For instance, in June 2020, SMT (Sahajanand Medical Technologies Pvt Ltd), the Indian market leader in coronary heart stent received the full reimbursement confirmation for its Supraflex and Supraflex Cruz from the Ministry of Health and Public Affairs of France.
Thus, the interplay of all the above-mentioned factors is likely to boost the vascular stents market in the forthcoming years.
However, the risk associated with vascular stents and the stringent regulatory approval process of the product is likely to impede the market growth.
In addition, the unprecedented COVID-19 outbreak has slowed down the global market for Vascular Stents during the initial phases. Nationwide lockdown, canceled or denied elective surgeries to prevent the transmission of the infection, disruptive supply chain due to logistical restriction across the border are some of the reasons that lead to the sluggish market growth of vascular stents. However, owing to the approval and administration of numerous COVID-19 vaccines across the globe in the second half of 2020, there was a significant improvement in the resumption of activities across various domains including healthcare services, thereby paving the way for a sound period of recovery for the vascular stents market.
Vascular Stents Market Segment Analysis:
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], EVAR Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon Expandable Stents and Self Expandable Stents), By End-User (Hospitals and Ambulatory Surgical Centers), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the Vascular Stents type segment, the drug-eluting stents are expected to hold a significant market share during the forthcoming years. The main advantage associated with the drug-eluting stents is that these stents are efficient in reducing the rates of in-stent restenosis after percutaneous coronary intervention (PCI) compared to bare-metal stents (BMS) in stable coronary artery disease. Various researches have demonstrated that Drug-eluting stents (DES) reduce the rate of restenosis by over 70% compared to BMS in native coronary lesions. Thus, at present the DES placement is believed to be preferred by the surgeon during PCI surgery, thereby increasing the demand for the DES vascular stents.
Moreover, the rise in research and development activities by the manufacturers actively developing vascular stents in the market to bring new products in the upcoming years is also expected to fuel the segmental market of vascular stents. For instance, Abbott in June 2020, initiated a clinical trial for its next-generation drug-eluting stent 48mm Study (SPIRIT 48). The purpose of the study is to evaluate the safety and effectiveness of the ABT NG DES 48 in improving coronary artery luminal diameter in subjects with coronary artery disease (CAD) due to de novo native coronary artery long lesions. Moreover, this clinical investigation will be conducted under an investigational device exemption (IDE) and is intended to support market approval of the ABT NG DES 48 in the United States. The study is expected to get complete by November 2022.
Additionally, approval of various vascular stents at present could also contribute to the segmental market growth. For instance, on October 16, 2020, Biosensors International Group Ltd (Biosensors) was granted a CE Mark for BioFreedom(TM) Ultra, their new drug-coated coronary stent system.
Hence, all the aforementioned factors are projected to drive the segmental growth of the vascular stent market in the forthcoming years.
North America is expected to dominate the overall Vascular Stents Market:
Among all the regions, North America is expected to occupy a major share in the overall vascular stents market during the forecasted period. This is owing to the rising obesity levels, rising hypertension among the population, increase in alcohol consumption, and smoking which often leads to various cardiovascular disorders such as coronary heart and peripheral vascular disorders which require vascular stenting as a treatment. In addition, the growing geriatric population, rapid technological advancements coupled with the increasing healthcare expenditures in the region have spurred the demand for vascular stents.
Further, in the US, as per the report published by the Centers for Disease Control and Prevention in the year 2023, approximately 6.5 million people age 40 and older in the US have Peripheral Artery Diseases (PAD) in the same year.
Also, as per the above-mentioned source, the US obesity prevalence was 42.4% in 2017 - 2018 which tremendously increased from the last decade when it was 30.5% of the total US population. Through various researches, it has been concluded that obesity has an important role in atherosclerosis and coronary artery disease.
Moreover, the presence of key market players and their strategic business activities such as collaboration, approval, and launch of the product, among others are likely to bolster the regional vascular stent market in the upcoming years. For instance, in October 2020, Medtronic received approval from the US Food and Drug Administration (FDA) for its Abre Venous Self-expanding Stent System to treat deep venous obstruction, a medical condition that may limit blood flow from the leg and lead to swelling of the leg and pain when walking.
Hence, the interplay of all the above-mentioned factors is projected to spur the vascular stents market in the region during the forecasted period.
Furthermore, the Asia-Pacific region has the future potential growth for the global vascular stents market. The adoption of a sedentary lifestyle among the population which significantly increases the risk of coronary heart disease, and other vascular disorders is the key driving factor for the vascular stents market. In addition, the rising geriatric population in the region, improving healthcare infrastructure, and rise in disposable income, among others, are some of the factors which make the APAC region the fastest growing market for vascular stents during the forecasted period.
Vascular Stents Market Key Players:
Some of the key market players operating in the Vascular Stents market include Medtronic, Abbott, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, B. Braun Melsungen AG, Terumo Corporation, eucatech AG, MicroPort Scientific Corporation., Meril Life Sciences Pvt. Ltd., Vascular Concepts (SMT), W. L. Gore & Associates, Inc., Becton, Dickinson and Company., ENDOLOGIX LLC., Biosensors International Group, Ltd., Lombard Medical, Translumina GmbH, JOTEC GmbH, iVascular, Cordis, Cook, SCITECH, and others.
Recent Developmental Activities in the Vascular Stents Market:
In August 2020, Boston Scientific Corporation received FDA approval for SYNERGY(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System (Monorail(TM)), SYNERGY(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System (Over-The-Wire(TM)), and SYNERGY(TM) XD Everolimus-Eluting Platinum Chromium Coronary Stent System (Monorail(TM)) is indicated for use in patients who have a narrowing in their coronary arteries and are at high risk for bleeding.
In July 2020, INSPIRON Coronary Sirolimus-Eluting Stent from SCITECH Medical received CE Mark approval.
In May 2020, SMT (Sahajanand Medical Technologies Pvt. Ltd) acquired the structural heart medical device firm Vascular Concepts, providing cutting-edge medical devices for the treatment of arterial diseases.
Key Takeaways from the Vascular Stents Market Report Study
Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Vascular Stents market.
Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
Key companies dominating the Global Vascular Stents Market.
Various opportunities available for the other competitor in the Vascular Stents Market space.
What are the top-performing segments in 2023? How these segments will perform in 2030.
Which are the top-performing regions and countries in the current market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Vascular Stents market growth in the coming future?
Target Audience who can be benefited from the Vascular Stents Market Report Study
Vascular Stents providers
Research organizations and consulting companies
Vascular Stents-related organization, association, forum, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders in Vascular Stents
Various End-users who want to know more about the Vascular Stents Market and the latest technological developments in the Vascular Stents market.
Frequently Asked Questions for the Vascular Stents Market:
Vascular stents are small tubular scaffolds widely used in the treatment of narrowing of the vessel to prevent acute vessel closure and late restenosis in a variety of vessels such as coronary arteries.
The global vascular stents market was valued at USD 13.31 billion in 2023, growing at a CAGR of 7.90% during the forecast period from 2024 to 2030, to reach USD 21.01 billion by 2030.
The major factor driving the demand for Vascular Stents is the growing prevalence of vascular disorders such as atherosclerosis, carotid artery diseases, and peripheral artery diseases, among others. Moreover, rising preferences for minimally invasive surgeries among the patient population, increasing technological advancement in the product arena, and approval of various vascular stents, among others are some of the factors responsible for driving the global vascular stents market in the forthcoming years.
Some of the key market players operating in the Vascular Stents market include Medtronic, Abbott, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, B. Braun Melsungen AG, Terumo Corporation, eucatech AG, MicroPort Scientific Corporation., Meril Life Sciences Pvt. Ltd., Vascular Concepts (SMT), W. L. Gore & Associates, Inc., Becton, Dickinson and Company., ENDOLOGIX LLC., Biosensors International Group, Ltd., Lombard Medical, Translumina GmbH, JOTEC GmbH, iVascular, Cordis, Cook, and others.
Among all the regions, North America is expected to occupy a major share in the overall vascular stents market during the forecast period, 2024-2030. This is owing to the rising obesity levels, rising hypertension among the population, increase in alcohol consumption, and smoking which often leads to various cardiovascular disorders such as coronary heart and peripheral vascular disorders which require vascular stenting as a treatment. In addition, the growing geriatric populations, rapid technological advancements coupled with the increasing healthcare expenditures in the region have spurred the demand for vascular stents.